Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 314

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

HYPERLIPIDEMIA IN SOLID ORGAN TRANSPLANTATION

Kobashigawa, Jon A., Kasiske, Bertram L.·1997·Transplantation

Abstract

In the past decade, improved management strategies in solid organ transplantation have dramatically increased allograft survival and reduced early posttransplant morbidity. However, these advances have been accompanied by the emergence of a new group of complications. One of these complications, hyperlipidemia, is an important concern in heart and kidney transplant recipients and may also be a concern in the liver transplant population (1). Because of the well-established correlation between lipid levels and atherosclerosis in nontransplant populations (2), it is logical to expect that transplant recipients would also be placed at increased risk for cardiovascular events. In addition, there is emerging evidence linking elevated lipid levels to allograft vasculopathy, an unusually accelerated form of atherosclerotic vascular disease (3). In fact, this complication has emerged as one of the primary causes of morbidity and mortality in long-term transplant survivors, surpassing even infection. In this Overview, the mechanisms and clinical implications of hyperlipidemia in the heart, kidney, and liver transplant populations are discussed, with comments specific for each of these three transplant groups, and treatment options are reviewed. POTENTIAL CAUSES OF HYPERLIPIDEMIA Potential causes of hyperlipidemia in transplant recipients include diet, genetic predisposition, and immunosuppressive medications. Many patients are at or below their ideal body weight before transplantation, but become obese after successful procedures. Obesity in heart transplantation has been closely associated with the development of hyperlipidemia (4). Some patients with preoperative diagnosis of atherosclerotic cardiovascular disease have familial hyperlipidemia. This genetic predisposition contributes to the posttransplant hyperlipidemic state (5). Immunosuppressive agents, such as corticosteroids and cyclosporine, are implicated in the development of hyperlipidemia, and possible mechanisms are described in Figure 1. It has been suggested that cyclosporine may inhibit the enzyme 26-hydroxylase, which is important in the bile acid synthetic pathway (6). Cyclosporine would thereby decrease the synthesis of bile acids from cholesterol and subsequently the transport of cholesterol to the intestines. Cyclosporine is also reported to bind to the low-density lipoprotein (LDL*) receptor, which results in increased serum levels of LDL cholesterol (6). It is also thought that cyclosporine increases hepatic lipase activity and decreases lipoprotein lipase activity, resulting in impaired clearance of very low-density lipoprotein (VLDL) and LDL. Corticosteroids are reported to enhance the activity of acetyl-coenzyme A carboxylase and free fatty acid synthetase, increase hepatic synthesis of VLDL, down-regulate LDL receptor activity, increase the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, and inhibit lipoprotein lipase (7-9). This results in increased levels of VLDL, total cholesterol, and triglyceride levels, and decreased high-density lipoprotein (HDL) levels. POSSIBLE CONSEQUENCES OF POSTTRANSPLANT HYPERCHOLESTEROLEMIA Hypercholesterolemia in organ transplant recipients may be associated with an increased risk for allograft vasculopathy. In cardiac transplant recipients, transplant vasculopathy takes the form of transplant coronary artery disease (CAD); in renal transplant recipients, vasculopathy manifests as chronic rejection; in hepatic transplantation, it manifests as vanishing bile duct syndrome (3). Atherosclerotic vascular disease in nontransplant vessels is another possible consequence. It has been reported that 55% of deaths in renal transplant recipients with functioning allografts were cardiovascular related (10). Peripheral vascular disease has been reported in 10% of heart transplant recipients (11). HEART TRANSPLANT RECIPIENTS Lipid abnormalities are reported in 60-80% of heart transplant patients receiving the standard triple-drug regimen consisting of cyclosporine, azathioprine, and prednisone (12). Several groups have examined the patterns of lipid abnormalities following cardiac transplantation. Studies in this population show that increases in total cholesterol, LDL cholesterol, apolipoprotein B, and triglyceride levels develop at 3-18 months (13, 14). Some studies suggest that these lipid levels slowly fall as the time after transplantation lengthens (4). The reports are more variable regarding levels of HDL cholesterol (15, 16). Interestingly, lipoprotein(a) levels have been found to decrease by almost 40% after cardiac transplantation (16). Ballantyne et al. (13) reported that mean total cholesterol values in 100 cardiac transplant recipients increased from pretransplant levels of 168±7 mg/dl to 234±7 mg/dl at 3 months after transplantation. During this same period, LDL cholesterol rose from 111±6 mg/dl to 148±6 mg/dl, HDL cholesterol rose from 34±1 mg/dl to 47±1 mg/dl, and triglyceride levels r

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007890-199702150-00001

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 314

Metadata

Authors
Kobashigawa, J. A., & Kasiske, B. L.
Venue
Transplantation
Published
1997-02
Volume
63
Issue
3
Pages
331-338
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2093162411
Cited by
314
References
38
FWCI
16.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HYPERLIPIDEMIA IN SOLID ORGAN TRANSPLANTATION. https://app.cochat.ai/papers/10.1097/00007890-199702150-00001
The paper
Kobashigawa, J. A., & Kasiske, B. L. (1997). HYPERLIPIDEMIA IN SOLID ORGAN TRANSPLANTATION. Transplantation. https://doi.org/10.1097/00007890-199702150-00001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.